Advisory Committees
-
Briefing Information for the March 18, 2009 Meeting of the Cardiovascular and Renal Drugs Advisory Committee
Vision impaired people having problems accessing certain pages of a PDF file
may call (301) 796-3634 for assistance
FDA
Disclaimer
Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. ยง 552).
FDA Briefing Material [PDF]
Sanofi-Aventis
Disclaimer
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Briefing Material [PDF]
-
-







